In its latest quarterly filing, SenesTech reported ongoing net losses reflecting its growth-stage operating profile but reinforced strategic advancements in distribution and international regulatory approvals. The company’s proprietary non-lethal rodent control product, Evolve, remains central to its business model, leveraging unique technology and expanding retail partnerships to penetrate niche markets domestically and abroad. While financial sustainability challenges persist, governance focused on cybersecurity risk management and operational control underpins resilience amid competitive and regulatory complexities.